AI Summary
✦ ClarthaCipla is a pharmaceutical manufacturer selling generic and branded generic medicines, vaccines, APIs, and formulations. India, the United States, and South Africa anchor its geographic revenue base, across respiratory, HIV/AIDS, cardio-metabolic, oncology, and other therapies. Its consumer healthcare, biosimilars, and specialty businesses provide additional revenue streams. The announced ₹300 crore Karnataka expansion with Rocket India could support future manufacturing capacity, but current revenue growth remains limited at 2.1%. Profit fell 26.4% year-on-year as margins declined, indicating earnings pressure despite positive market sentiment. ROE is unavailable, while debt-to-equity of 1.78 indicates leverage could amplify any deterioration in returns. At 35.1 times earnings, Cipla appears rich relative to its low growth and declining profitability. Investors must assess whether expansion and specialty products can offset margin compression and leverage-related risk.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 36 analysts
Fundamentals
Fundamentals institutional score is 17 using growth durability 17.0.
Valuation
Valuation institutional score is 44 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 47 using mean target upside 2.8%; dispersion penalty 15.9; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 89 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 8 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. technical structure provide support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 1.7% above historical median. Valuation is stable — currently in the overvalued zone (z-score: +0.46). Confidence: 91%.
Live forward EPS implies next-12-month EPS of ₹63.47. Applying the stock's normalized valuation corridor produces a fair range of ₹2,021.52 to ₹2,269.69, with base value near ₹2,190.35 (+49.2% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹63.47
Forward P/E
23.1x
Base Fair Value
₹2,190.35
Fair Range
₹2,021.52 - ₹2,269.69
Upside To Base
+49.2%
Estimate Source
Live forward EPS
Growth Estimate
-39.2%
5Y Average
29.75
Current
35.09
Overvalued
35.76
Undervalued
31.85
5Y Average
17.83
Current
21.08
Overvalued
21.10
Undervalued
14.05
5Y Average
3.57
Current
4.22
Overvalued
4.11
Undervalued
3.04
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.7x Premium | +96% vs avg | +36.2% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.0x Undervalued | -53% vs avg | +21.5% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.4x Premium | +23% vs avg | +0.8% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Fair | -12% vs avg | +11.2% |
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.9x Undervalued | -16% vs avg | +10.6% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -6% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | -4% vs avg | +31.7% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -27% vs avg | -3.9% |
CIPLA LTD trades in line with peers (35.2x vs avg 40.2x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include TORRENT PHARMACEUTICALS L, LUPIN LIMITED, MANKIND PHARMA LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹5.08K CrJun 2026Latest net profit
₹862 CrJun 2026Latest EPS
₹10.67Jun 2026Net margin
21.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,318 | 4,234 | 4,381 | 4,037 | 4,501 | 4,775 | 4,971 | 4,798 | 5,046 | 5,226 | 4,498 | 4,210 | 5,078 |
| Expenses + | 3,114 | 3,009 | 3,025 | 3,209 | 3,141 | 3,337 | 3,309 | 3,479 | 3,422 | 3,703 | 3,777 | 3,643 | 3,992 |
| Operating Profit | 1,205 | 1,225 | 1,356 | 828 | 1,360 | 1,438 | 1,662 | 1,319 | 1,624 | 1,523 | 721 | 567 | 1,086 |
| OPM % | 28% | 29% | 31% | 21% | 30% | 30% | 33% | 27% | 32% | 29% | 16% | 13% | 21% |
| Other Income + | 158 | 319 | 265 | 595 | 214 | 289 | 189 | 588 | 271 | 255 | 172 | 180 | 243 |
| Interest | 0 | 7 | 9 | 5 | 5 | 3 | 4 | 3 | 6 | 3 | 4 | 7 | 6 |
| Depreciation | 136 | 180 | 135 | 137 | 138 | 146 | 143 | 148 | 146 | 141 | 153 | 218 | 169 |
| Profit before tax | 1,226 | 1,358 | 1,477 | 1,281 | 1,430 | 1,578 | 1,704 | 1,756 | 1,744 | 1,633 | 736 | 522 | 1,154 |
| Tax % | 27% | 24% | 25% | 19% | 26% | 25% | 16% | 15% | 25% | 26% | 16% | 26% | 25% |
| Net Profit + | 895 | 1,030 | 1,114 | 1,038 | 1,056 | 1,178 | 1,438 | 1,485 | 1,303 | 1,211 | 617 | 385 | 862 |
| EPS in Rs | 11.09 | 12.75 | 13.80 | 12.86 | 13.08 | 14.59 | 17.81 | 18.39 | 16.13 | 14.99 | 7.64 | 4.76 | 10.67 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS